Lotus Pharmaceutical (1795) Stock Overview
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 1/6 |
1795 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lotus Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$196.50 |
| 52 Week High | NT$369.50 |
| 52 Week Low | NT$170.50 |
| Beta | 0.64 |
| 1 Month Change | 4.24% |
| 3 Month Change | -2.24% |
| 1 Year Change | 1.29% |
| 3 Year Change | -20.77% |
| 5 Year Change | 83.64% |
| Change since IPO | 59.11% |
Recent News & Updates
Narrative Update • Aug 18
1795: Higher Margins And Complex Generics Launch Will Drive Future Repricing
Analysts have adjusted their view on Lotus Pharmaceutical, with the fair value estimate moving from NT$367 to NT$334 as they factor in revised assumptions for revenue growth, profit margins, and future P/E levels. What's in the News for Lotus Pharmaceutical No major recent news items for Lotus Pharmaceutical are available from the specified sources as of 17 Aug 2026.
Narrative Update • Jun 25
1795: Complex Generics Expansion And Lower Margins Will Shape Future P E Outlook
Analysts have revised their fair value estimate for Lotus Pharmaceutical to NT$200.0 from NT$311, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Lotus Pharmaceutical announced the global launch of its Nintedanib soft gel capsules in 100mg and 150mg strengths as part of its specialty and complex generics portfolio.Narrative Update • Jun 08
1795: Global Complex Generics Launch Will Drive Future Repricing
Analysts now set a slightly lower price target for Lotus Pharmaceutical, trimming it by about NT$1 while adjusting their assumptions on discount rate, revenue growth, profit margin, and future P/E to reflect a more balanced view of the stock. What's in the News Lotus Pharmaceutical announced the global launch of its Nintedanib soft gel capsules in 100mg and 150mg strengths as part of its specialty and complex generics portfolio.Recent updates
Narrative Update • Aug 18
1795: Higher Margins And Complex Generics Launch Will Drive Future Repricing
Analysts have adjusted their view on Lotus Pharmaceutical, with the fair value estimate moving from NT$367 to NT$334 as they factor in revised assumptions for revenue growth, profit margins, and future P/E levels. What's in the News for Lotus Pharmaceutical No major recent news items for Lotus Pharmaceutical are available from the specified sources as of 17 Aug 2026.Narrative Update • Jun 25
1795: Complex Generics Expansion And Lower Margins Will Shape Future P E Outlook
Analysts have revised their fair value estimate for Lotus Pharmaceutical to NT$200.0 from NT$311, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News Lotus Pharmaceutical announced the global launch of its Nintedanib soft gel capsules in 100mg and 150mg strengths as part of its specialty and complex generics portfolio.Narrative Update • Jun 08
1795: Global Complex Generics Launch Will Drive Future Repricing
Analysts now set a slightly lower price target for Lotus Pharmaceutical, trimming it by about NT$1 while adjusting their assumptions on discount rate, revenue growth, profit margin, and future P/E to reflect a more balanced view of the stock. What's in the News Lotus Pharmaceutical announced the global launch of its Nintedanib soft gel capsules in 100mg and 150mg strengths as part of its specialty and complex generics portfolio.
Narrative Update • May 25
1795: Expanded Respiratory Launch Will Support Higher Future Margins
Analysts have lifted their price target for Lotus Pharmaceutical to NT$500, citing updated assumptions that combine a steady fair value view with a slightly higher discount rate, a lower implied revenue growth rate, a higher projected profit margin, and a reduced future P/E multiple. What's in the News Lotus Pharmaceutical announced the global launch of Nintedanib soft gel capsules in 100mg and 150mg strengths across 30 markets, following approvals from regulators including the US FDA, European authorities, Health Canada and the Taiwan FDA (Key Developments).Narrative Update • May 01
1795: Higher P/E Assumptions And Leaner Margins Will Drive Future Upside
Analysts have revised their view on Lotus Pharmaceutical, maintaining the fair value at NT$500.00 while adjusting assumptions around revenue growth, profit margins, and future P/E. These changes together reshape how they view the risk and reward trade off at the current price target.Narrative Update • Apr 16
1795: Korea Presbyopia Filing And Regional Rights Will Drive Future Repricing
Narrative Update on Lotus Pharmaceutical Analysts have trimmed their fair value estimate for Lotus Pharmaceutical from NT$387.80 to NT$367.80, citing updated assumptions that combine slightly higher projected revenue growth with a lower profit margin outlook and a higher future P/E multiple. Valuation Changes Fair Value: NT$367.80 compared with the prior NT$387.80, reflecting a slightly lower central estimate for the shares.Narrative Update • Apr 01
1795: Higher Growth Assumptions And Lower P/E Multiple Will Drive Future Upside
Analysts have reduced their fair value estimate for Lotus Pharmaceutical from NT$600.00 to NT$500.00, reflecting updated assumptions around revenue growth, profit margins and a lower future P/E multiple. Valuation Changes Fair Value: Reduced from NT$600.00 to NT$500.00, a cut of roughly 17%.Narrative Update • Mar 18
1795: Korea Presbyopia Filing And Regional Rights Will Support Future Repricing
Analysts have trimmed their 12 month price target for Lotus Pharmaceutical from around NT$416 to about NT$388, reflecting updated assumptions for revenue growth, profit margins, and a slightly higher forward P/E multiple. Valuation Changes Fair Value: Trimmed from NT$415.8 to NT$387.8, a modest reduction in the estimated equity value.Narrative Update • Mar 04
1795: Higher Growth Assumptions And P E Outlook Will Support Upside Potential
Analysts have lifted their fair value estimate for Lotus Pharmaceutical from NT$273.0 to NT$311.0, reflecting updated assumptions for revenue growth, profit margins and future P/E, while making only modest adjustments to the discount rate. Valuation Changes Fair Value: NT$273.0 to NT$311.0, indicating a moderate upward revision in the estimate.Narrative Update • Feb 18
1795: Korea Presbyopia Filing And Regional Rights Will Support Future Upside
Analysts have kept their NT$415.8 price target for Lotus Pharmaceutical unchanged, citing minimal tweaks to the discount rate and implied future P/E assumptions rather than any shift in their core views on revenue growth or margins. What's in the News Lotus Pharmaceutical and LENZ Therapeutics reported that Lotus has submitted a New Drug Application to the Ministry of Food and Drug Safety in South Korea for VIZZTM, a treatment for presbyopia in adults (Key Developments).Narrative Update • Feb 03
1795: Southeast Asia Presbyopia NDA Will Support Future Share Price Upside
Analysts have lifted their price target on Lotus Pharmaceutical to $415.80 from $395.20, citing updated assumptions around revenue growth of 38.91%, profit margin of 22.13%, a 5.23% discount rate, and a forward P/E of 11.16x. What's in the News Lotus Pharmaceutical submitted a New Drug Application to the Ministry of Food and Drug Safety in South Korea for VIZZTM, an eye drop for presbyopia in adults, under its exclusive license with LENZ Therapeutics Inc.Narrative Update • Jan 20
1795: Presbyopia Drug Approval Progress Will Likely Not Justify Current Share Pricing
Analysts have raised their fair value estimate for Lotus Pharmaceutical from $215.00 to $273.00, citing updated assumptions that include revised revenue growth, profit margin, and future P/E inputs. What's in the News Lotus Pharmaceutical and LENZ Therapeutics submitted a New Drug Application to South Korea's Ministry of Food and Drug Safety for VIZZTM, targeting presbyopia treatment in adults in that market (Key Developments).Narrative Update • Jan 05
1795: Southeast Asia Presbyopia NDA Will Support Future Share Price Upside
Analysts kept their fair value estimate for Lotus Pharmaceutical steady at $395.20, with only minor tweaks to revenue growth, profit margin, discount rate and future P/E assumptions behind the updated target. What's in the News Lotus Pharmaceutical and LENZ Therapeutics reported that Lotus has submitted a New Drug Application to South Korea's Ministry of Food and Drug Safety for VIZZTM, a presbyopia treatment for adults, under their exclusive license and commercialization agreement signed in May 2025 for South Korea and certain Southeast Asian markets (Key Developments).Narrative Update • Dec 21
1795: Southeast Asia Presbyopia Franchise Will Drive Future Share Price Upside
Analysts have modestly reaffirmed their outlook on Lotus Pharmaceutical, keeping the target price effectively unchanged at around $395.20, as stable fair value estimates, discount rate assumptions, and forecasts for revenue growth, profit margins, and future P/E collectively support a steady valuation profile. What's in the News Lotus Pharmaceutical and LENZ Therapeutics submitted a New Drug Application to South Korea's Ministry of Food and Drug Safety for VIZZ, an eye drop treatment for presbyopia in adults.Narrative Update • Dec 07
1795: Future Southeast Asia Presbyopia Opportunity Will Drive Share Price Upside
Analysts have raised their price target on Lotus Pharmaceutical by approximately $17 to reflect a higher fair value estimate of about $395, even as they modestly temper assumptions for revenue growth and profit margins while assigning a richer future earnings multiple. What's in the News Lotus Pharmaceutical and LENZ Therapeutics submitted a New Drug Application to South Korea's Ministry of Food and Drug Safety for VIZZTM, an eye drop treatment for presbyopia in adults.Narrative Update • Nov 23
1795: Stronger Margins And Lower P/E Will Support Future Upside Potential
Analysts have raised their price target for Lotus Pharmaceutical, increasing it by $0.00. Recent projections reflect higher expected revenue growth and improved profit margins, along with a lower anticipated future price-to-earnings ratio.Narrative Update • Nov 06
1795: Stable Financials and Consistent Margins Will Support Ongoing Upside Potential
Analysts have maintained their price target for Lotus Pharmaceutical and have kept the fair value unchanged at $378.20, as current projections indicate stability in key financial metrics along with long-term growth assumptions. Valuation Changes Fair Value remained unchanged at NT$378.20.Narrative Update • Oct 23
Analysts Reaffirm Lotus Pharmaceutical Price Target Amid Stable Growth and Profitability Outlook
Analysts have maintained their price target for Lotus Pharmaceutical at $378.20. They cite stable growth and profitability projections as the basis for this unchanged outlook.Narrative Update • Oct 09
Alpha Choay Acquisition And New R&D Center Will Strengthen Southeast Asia Presence
Analysts have raised their fair value estimate for Lotus Pharmaceutical from $346.00 to $378.20. They cite stronger projected revenue growth, which more than offsets a slightly lower profit margin forecast.Narrative Update • Sep 25
Alpha Choay Acquisition And New R&D Center Will Strengthen Southeast Asia Presence
The upward revision in Lotus Pharmaceutical's consensus price target reflects sharply improved revenue growth forecasts and a substantially lower future P/E, raising the fair value estimate from NT$322.40 to NT$346.00. Valuation Changes Summary of Valuation Changes for Lotus Pharmaceutical The Consensus Analyst Price Target has risen from NT$322.40 to NT$346.00.Narrative Update • Aug 19
Alpha Choay Acquisition And New R&D Center Will Strengthen Southeast Asia Presence
The downward revision in Lotus Pharmaceutical’s price target primarily reflects reduced analyst expectations for both revenue growth and net profit margin, resulting in a new consensus fair value of NT$334.80. What's in the News Completed buyback of 3,650,000 shares (1.38%) for TWD 780.99 million, fulfilling April 10, 2025 buyback plan.Analysis Article • Mar 29
Why Investors Shouldn't Be Surprised By Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Low P/E
Lotus Pharmaceutical Co., Ltd.'s ( TWSE:1795 ) price-to-earnings (or "P/E") ratio of 12.7x might make it look like a...
New Narrative • Mar 15
Alpha Choay Acquisition And New R&D Center Will Strengthen Southeast Asia Presence
Strategic acquisitions and alliances are bolstering Lotus Pharmaceutical's growth and diversification, particularly in Southeast Asia.Analysis Article • Feb 24
Lotus Pharmaceutical (TWSE:1795) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Dec 04
Market Cool On Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Earnings
With a price-to-earnings (or "P/E") ratio of 17.6x Lotus Pharmaceutical Co., Ltd. ( TWSE:1795 ) may be sending bullish...Analysis Article • Nov 16
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Lotus Pharmaceutical Co., Ltd. ( TWSE:1795 ) shareholders are probably feeling a little disappointed, since its shares...Analysis Article • Nov 14
Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem
Lotus Pharmaceutical Co., Ltd. ( TWSE:1795 ) just reported some strong earnings, and the market reacted accordingly...Analysis Article • Oct 23
Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next
It's shaping up to be a tough period for Lotus Pharmaceutical Co., Ltd. ( TWSE:1795 ), which a week ago released some...Analysis Article • Jul 18
Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)
When close to half the companies in Taiwan have price-to-earnings ratios (or "P/E's") above 24x, you may consider Lotus...Analysis Article • Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price
With a price-to-earnings (or "P/E") ratio of 20.8x Lotus Pharmaceutical Co., Ltd. ( TWSE:1795 ) may be sending bullish...Analysis Article • Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals
Lotus Pharmaceutical Co., Ltd. ( TWSE:1795 ) announced strong profits, but the stock was stagnant. Our analysis...Shareholder Returns
| 1795 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 8.9% | 4.8% | -1.4% |
| 1Y | 1.3% | -24.2% | 87.5% |
Return vs Industry: 1795 exceeded the TW Pharmaceuticals industry which returned -24.2% over the past year.
Return vs Market: 1795 underperformed the TW Market which returned 87.5% over the past year.
Price Volatility
| 1795 volatility | |
|---|---|
| 1795 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in TW Market | 11.8% |
| 10% least volatile stocks in TW Market | 2.7% |
Stable Share Price: 1795 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1795's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | n/a | Petar Vazharov | www.lotuspharm.com.tw |
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services.
Lotus Pharmaceutical Co., Ltd. Fundamentals Summary
| 1795 fundamental statistics | |
|---|---|
| Market cap | NT$52.31b |
| Earnings (TTM) | NT$3.77b |
| Revenue (TTM) | NT$28.49b |
13.9x
P/E Ratio1.8x
P/S RatioIs 1795 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1795 income statement (TTM) | |
|---|---|
| Revenue | NT$28.49b |
| Cost of Revenue | NT$13.17b |
| Gross Profit | NT$15.31b |
| Other Expenses | NT$11.55b |
| Earnings | NT$3.77b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.15 |
| Gross Margin | 53.75% |
| Net Profit Margin | 13.22% |
| Debt/Equity Ratio | 236.8% |
How did 1795 perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield18%
Payout RatioDoes 1795 pay a reliable dividends?
See 1795 dividend history and benchmarks| Lotus Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Aug 31 2026 |
| Dividend Pay Date | Oct 05 2026 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 43 days |
Does 1795 pay a reliable dividends?
See 1795 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/22 20:24 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lotus Pharmaceutical Co., Ltd. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hsuan Chen | KGI Securities Co. Ltd. |
| Hsiu Chi Lin | Masterlink Securities Investment Advisory |
| Yijun Chen | SinoPac Securities Investment Service |